Have to admit that all this talk of an acquisition makes me a little leary. The company is currently in the middle of crossing a bridge that many small medical companies have had a problem navigating. Going from a primarily research and development company to a full fledged commercial enterprise. Having the management team distracted with the additional burden of coordinating and digesting an acquisition is a significant task. I hope they do not overreach.
Maybe the current product offering of TEI means nothing. Maybe all we are buying is a sales force that has had to grind it out, along with their relationships internally within hospitals. Maybe the cost will not reflect much of a premium when you consider Arun wants to be way out in front of competation to solidify Novadaq. When you have a winner and want to roll their is some slop along the way but its easily overcome by increased sales. I'm only concerned we can manufacture as fast as we will need too. Who knows maybe NVDQ technology will enhance what TEI has been doing. Just icing on the cake.... All large growth opportunities come with risk... I hope Arun is thinking big... I believe that's an understatement.